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NATURAL HISTORY OF POSTTHROMBOTIC
DISEASE: TRANSITION FROM ACUTE TO
CHRONIC DISEASE
—Susan R. Kahn, MD, MSc, FRCPC, Montreal,
Canada
Despite appropriate anticoagulant therapy, at least 1 of
every 2 to 3 patients with acute symptomatic deep-vein
thrombosis (DVT) of the lower extremities will develop
postthrombotic disease (PTD), which is severe in 1 of 5
patients.1-3 The reported incidence of PTD after confirmed
symptomatic venous thrombosis has varied between 20%
and 100%. Rates have been higher in earlier studies4-7 than
in reviews of later (last 
20 years) studies,1,2 which could
be due to improved diagnostic and therapeutic approaches
to patients with DVT, but also to differences among studies
in study design, definition of PTD, sample size, length of
follow-up, and use of elastic compression stockings. PTD
can also develop, although less frequently, after an asymp-
tomatic episode of postoperative DVT.8,9
According to the results of the most recent studies,
most patients who develop PTS become symptomatic
within 2 years of the acute episode of DVT.1,3,10-19 These
findings challenge the view that PTD requires many years
to become apparent. Furthermore, a recent study showed
that the degree of severity of persistent venous symptoms or
signs as early as 1 month after DVT predicted PTD in a
“dose-response” fashion during the subsequent 2 years.3
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quence of venous hypertension. Venous hypertension leads
to impaired venous return, reduced calf muscle perfusion,
abnormal function of the microvasculature with increased
tissue permeability, and consequently the characteristic
clinical manifestations of PTD.2,20 DVT can lead to
chronic venous hypertension by two main mechanisms,
persistent (residual) venous obstruction, and valvular re-
flux, which may occur in combination.17,21-28 Of the two
mechanisms, persistent venous obstruction may be more
important than reflux, as based on two recent reports, lack
of vein recanalization within 6 months after DVT alone or
in combination with venous reflux significantly predicted
the development of PTD, whereas the presence of venous
reflux alone had only modest predictive value.16,29 Anticoag-
ulant treatment of DVT prevents thrombus extension and
pulmonary embolization, but does not lyse the acute clot.
Follow-up studies of patients with DVT treated with antico-
agulants have revealed that often only partial clearance of
thrombus occurs.29-32 Damage to venous valves with subse-
quent reflux occurs often after DVT, likely via thrombus-
induced activation of inflammation, fibrous scarring associ-
ated with acute and resolving thrombosis, or by venous
dilation distal to the obstructed venous segment.33-36 Of
interest, in two recent reports, increased levels of inflamma-
tory cytokines or adhesion molecules were linked with the
subsequent development of PTD,37,38 suggesting that in-
flammation at the timeof acuteDVTor residual inflammation
after the acute episode ofDVTmay play a role in the transition
from acute DVT to chronic PTD.
Clinical predictors of chronic PTD identifiable at the
time of acute DVT include proximal DVT (especially com-
mon femoral or iliac veins), elevated body mass index,
previous ipsilateral DVT and older age.2,39 One study has
reported that patients with DVT with subtherapeutic inter-
national normalized ratios 50% of the time during the
initial 3-month treatment with vitamin K antagonists had a
threefold higher risk of developing PTS.40 Despite the
common belief that patients with PTD have a uniformly
poor prognosis, a few recent studies have suggested that
prognosis might be better than previously reported, with
more than 50% of patients remaining stable or even improv-
ing during long-term follow-up.3,41,42 However, cur-
rently, it is not possible to reliably predict the course of
PTD in individual patients.
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CRITICAL ISSUES IN DEEP VEIN
THROMBOSIS PREVENTION
—J.A. Caprini, MD, Chicago, Ill
Despite a great deal of literature including thousands of
studies showing the value of thrombosis prophylaxis inmedical and surgical patients, only 50% of the patients “at
risk” for thromboembolism worldwide receive appropriate
prophylaxis. Although there is a great fear of bleeding from
prophylactic anticoagulants, large studies have shown that
people die from thrombosis without prophylaxis rather
than bleeding from anticoagulation. These statistics are
astonishing given the fact that approximately 900,000 in-
dividuals suffer venous thromboembolism (VTE) in the
United States yearly including 300,000 deaths. The major-
ity of VTE events occur after discharge where prophylaxis is
uncommon. The expense and inconvenience of out-of-
hospital prophylaxis and lack of randomized control trials
(RCTs) for most patient groups have limited this approach.
A further problem is health care providers have been taught
to follow CHEST consensus guidelines that are a good
source of RCT data but do not apply to many patients in
clinical practice.
Part of the solution is to perform individual risk
assessment for each patient and calculate a score that has
been shown to correlate with the 30-day incidence of
imaging-proven clinical VTE events. The score needs to
be linked to a care pathway that is mandatory but in-
cludes a provision to opt out for valid contraindications.
The second approach is to expand and develop real world
clinical databases and have a section in the CHEST
guidelines document that analyzes and rates these data-
bases. Furthermore recommendations and clinical care
plans based on these databases can be suggested. Me-
chanical methods of prophylaxis have to be critically
analyzed and differences between stockings and pneu-
matic devices that have been identified in the literature
need to be widely disseminated. There needs to be a
method developed to track compliance with pneumatic
devices and also standardize them. Head to head studies
need to be done to see which of several approaches has
the best efficacy (long leg, short leg, uniform compres-
sion, sequential compression, rapid inflation).
Finally, the most important need for the prophylaxis
field is the development of safer but effective modalities.
Research involving the P-selectin or its ligand, PSGL-1, (a
leukocyte cellular adhesion molecule) is a critical issue
because preliminary data have shown that these compounds
have been shown to be effective in reducing inflammation
and thrombus resolution comparable to the low molecular
weight heparin in animals.
CRITICAL ISSUES
1. The use of individual risk assessment as a guide to
thrombosis prophylaxis including risk-scoring tied to
30-day known thrombosis rates to identify which pa-
tients would benefit from out-of-hospital prophylaxis.
2. Development of studies designed to explore new anti-
coagulants including the value of P-selectin inhibition as
a possible replacement for lowmolecular weight heparin
for thrombosis prophylaxis.
3. Meta-analysis of clinical databases to develop clinical
guidelines to supplement the CHEST consensus guide-
